Christopher Kohl
Overview
Explore the profile of Christopher Kohl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Surivet J, Jacob E, Kessler M, Kohl C, Vaillant C, Bezencon O, et al.
Bioorg Med Chem
. 2025 Mar;
122:118132.
PMID: 40048842
We describe the optimization of 2-acyl-1-biarylmethylpyrazolidines, a novel class of dual orexin receptor antagonists (DORAs) designed for the treatment of sleep disorders requiring a rapid onset (<30 min) and a...
2.
Surivet J, Kessler M, Vaillant C, Aissaoui H, Bezencon O, Busch L, et al.
Bioorg Med Chem
. 2024 Sep;
112:117892.
PMID: 39236468
Dual orexin receptor antagonists (DORAs) are approved for the treatment of sleep onset and/or sleep maintenance insomnia. In the present disclosure, we report the discovery of a new class of...
3.
Rueedi G, Panchaud P, Friedli A, Specklin J, Hubschwerlen C, Blumstein A, et al.
J Med Chem
. 2024 May;
67(11):9465-9484.
PMID: 38753983
() is one of the leading causes of healthcare-associated infections worldwide. The increasing incidence of strains resistant to currently available therapies highlights the need for alternative treatment options with a...
4.
Piali L, Birker-Robaczewska M, Lescop C, Froidevaux S, Schmitz N, Morrison K, et al.
Pharmacol Res Perspect
. 2017 Dec;
5(6).
PMID: 29226621
Sphingosine-1-phosphate receptor 1 (S1P ) modulators sequester circulating lymphocytes within lymph nodes, thereby preventing potentially pathogenic autoimmune cells from exiting into the blood stream and reaching inflamed tissues. S1P receptor...
5.
Birker-Robaczewska M, Bolli M, Rey M, de Kanter R, Kohl C, Lescop C, et al.
Mol Pharmacol
. 2017 Dec;
93(2):109-118.
PMID: 29203519
S1P (sphingosine-1-phosphate receptor 1) agonists prevent lymphocyte egress from secondary lymphoid organs and cause a reduction in the number of circulating blood lymphocytes. We hypothesized that S1P receptor modulators with...
6.
de Kanter R, Kohl C
Biopharm Drug Dispos
. 2017 Jun;
38(7):443-444.
PMID: 28656708
No abstract available.
7.
Surivet J, Zumbrunn C, Bruyere T, Bur D, Kohl C, Locher H, et al.
J Med Chem
. 2017 Apr;
60(9):3776-3794.
PMID: 28406300
There is an urgent unmet medical need for novel antibiotics that are effective against a broad range of bacterial species, especially multidrug resistant ones. Tetrahydropyran-based inhibitors of bacterial type II...
8.
Lescop C, Muller C, Mathys B, Birker M, de Kanter R, Kohl C, et al.
Eur J Med Chem
. 2016 Apr;
116:222-238.
PMID: 27061986
In a previous communication we reported on the discovery of alkylamino pyridine derivatives (e.g. 1) as a new class of potent, selective and efficacious S1P1 receptor (S1PR1) agonists. However, more...
9.
Bolli M, Lescop C, Birker M, de Kanter R, Hess P, Kohl C, et al.
Eur J Med Chem
. 2016 Mar;
115:326-41.
PMID: 27027817
In a previous communication we reported on the discovery of aminopyridine 1 as a potent, selective and orally active S1P1 receptor agonist. More detailed studies revealed that this compound is...
10.
de Kanter R, Sidharta P, Delahaye S, Gnerre C, Segrestaa J, Buchmann S, et al.
Clin Pharmacokinet
. 2015 Sep;
55(3):369-80.
PMID: 26385839
Introduction: Macitentan is a novel dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH). It is metabolized by cytochrome P450 (CYP) enzymes, mainly CYP3A4, to its active...